Health ❯ Healthcare ❯ Clinical Trials ❯ Cancer Treatment

Multiple Myeloma

Exicure’s Burixafor Delivers About 90% Stem-Cell Mobilization in Phase 2 as Shares Surge

Rapid one-hour peak with a clean safety profile positions the CXCR4 antagonist for Phase 3 planning.

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show